Clinical Trial Update: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial evaluating autologous CSPG4-targeted CAR-T cells for relapsed or refractory head and neck squamous cell carcinoma, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Autologous CSPG4-targeted CAR-T cells (CSPG4-directed CAR-T cells)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Head and Neck Cancer, Relapse | Phase 1, Phase 2 | Status: RECRUITING